Are there increased infection risks with methotrexate in seniors?

Do seniors face higher infection risk when taking methotrexate?

Seniors show higher rates of serious infections on methotrexate than younger adults. This pattern appears in large registry studies and insurance claims data, where the absolute risk rises steadily after age 65. The main drivers are reduced kidney function, weaker immune response, and the frequent use of other drugs that also suppress immunity.

How does kidney function change the picture?

Methotrexate is cleared mainly by the kidneys. After age 65, average creatinine clearance drops, so even standard weekly doses can reach higher blood levels for longer. Dose adjustments and closer lab monitoring are standard recommendations once estimated GFR falls below 60 mL/min.

Are infection rates different when methotrexate is used for cancer versus autoimmune disease?

In oncology settings, high-dose regimens produce brief but deep drops in white-cell counts, while rheumatology doses are lower and continuous. Seniors on weekly low-dose methotrexate still show an excess of pneumonia, shingles, and urinary-tract infections compared with age-matched controls not taking the drug.

What happens when methotrexate is combined with steroids or biologics?

Adding prednisone above 5 mg daily or a TNF inhibitor roughly doubles the infection incidence in Medicare data. The risk climbs further when two or more immunosuppressants are used together, especially in patients with COPD or diabetes.

Do vaccination guidelines change for seniors on methotrexate?

Current recommendations call for pneumococcal, influenza, recombinant shingles, and COVID-19 vaccines before or early in therapy. Live vaccines are avoided. Antibody responses can be blunted, so some centers check titers and offer boosters when protection is inadequate.

When does the infection risk drop after stopping methotrexate?

Most opportunistic infections occur while patients remain on therapy. Within three to six months after discontinuation, infection rates in observational cohorts converge toward those of similar-aged non-users, provided no other immunosuppressants are continued.

Are there alternatives that carry lower infection risk for older adults?

Leflunomide, hydroxychloroquine, and several JAK inhibitors have been compared head-to-head in elderly rheumatoid-arthritis patients. Hydroxychloroquine shows the lowest infection signal but weaker efficacy for joint disease. Some clinicians rotate to these agents or use short bridging courses of low-dose steroids when methotrexate must be paused.